List of Progress in Hematology "Review Series" 2011-2013
***2013***
Recent advances in genetic basis of childhood hemato-oncological diseases (Edited by Shuki Mizutani)
1. Urayama KY, Chokkalingam AP, Manabe A, Mizutani S. Current evidence for an inherited genetic basis of childhood acute
lymphoblastic leukemia. Int. J. Hematol. 97:3-19, 2013
2. Sakaguchi H, Nakanishi K, Kojima S. Inherited bone marrow failure syndromes in 2012. Int. J. Hematol. 97:20-29, 2013
3. Aoki Y, Matsubara Y. Ras/MAPK syndromes and childhood hemato-oncological diseases. Int. J. Hematol. 97:30-36, 2013
4. Mizutani S, Takagi M. XCIND as a genetic disease of X-irradiation hypersensitivity and cancer Susceptibility. Int. J. Hematol.
97:37-42, 2013
Genetic and epigenetic alterations in hematopoietic malignancies (Edited by Toshio Kitamura)
1.
Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int. J. Hematol. 97:165-174, 2013
2.
Yamazaki J, Issa J-P.J. Epigenetic aspects of MDS and its molecular targeted therapy. Int. J. Hematol. 97:175-182, 2013
3.
Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders Int. J. Hematol. 97:183-197, 2013
4.
Vu LP., Luciani L, Nimer SD. Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic
potential Int. J. Hematol. 97:198-209, 2013
Basic and Clinical Updates in Multiple Myeloma (Edited by Masahiro Kizaki)
1. Hosen N, Multiple myeloma-initiating cells. Int. J. Hematol. 97:306-312, 2013
2. Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int. J. Hematol. 97:313-323, 2013
3. Hideshima T, Anderson KC. Histone deacetylase inhibitors in the treatment for multiple myeloma Int. J. Hematol. 97:324-322, 2013
4. Watanabe R, Tokuhira M, Kizaki M. Current approaches for the treatment of multiple myeloma. Int. J. Hematol. 97:333-344, 2013
***2012***
Dysplastic myelopoiesis—from the second JSH International Symposium (Edited by Yasushi Miyazaki)
1. Nikoloski G, van der Reijden BA, Jansen JH. Mutations in epigenetic regulators in myelodysplastic syndromes.
Int.
J.
Hematol. 95:8-16, 2012
2. Raaijmakers MH. Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis. Int.
J. Hematol. 95:17-25, 2012
3. Ornstein MC, Sekeres MA.. Combination strategies in myelodysplastic syndromes. Int. J. Hematol. 95:26-33, 2012
Vascular biology with relation to hematopoiesis (Edited by Nobuyuki Takakura)
1. Matsui H. Endothelial progenitor cell-based therapy for hemophilia A. Int. J. Hematol. 95:119-124, 2012
2. Mizukami Y, Sasajima J, Ashida T, Kohgo Y. Abnormal tumor vasculatures and bone marrow-derived pro-angiogenic cells in cancer.
Int. J. Hematol. 95:125-130, 2012
3. Heissig B, Ohki-Koizumi M, Tashiro Y, Gritli I, Sato-Kusubata K, Hattori K. New functions of the fibrinolytic system in bone
marrow cell-derived angiogenesis. Int. J. Hematol. 95:131-137, 2012
4. Takakura N. Involvement of non-vascular stem cells in blood vessel formation. Int. J. Hematol. 95:138-142, 2012
Radiation injury to human body—acute and late hematopoietic organ damage (Edited by Masao Tomonaga)
1. Asano S. Current status of hematopoietic stem cell transplantation for acute radiation syndromes. Int. J. Hematol. 95: 227-231, 2012
2. Tsushima H, Iwanaga M, Miyazaki Y. Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic
syndromes. Int. J. Hematol. 95:232-238, 2012
3. Masuda Y, Kamiya K. Molecular nature of radiation injury and DNA repair disorders associated with radiosensitivity. Int. J.
Hematol. 95:239-245, 2012
Current understanding of thrombosis and hemostasis—from bench to bedside (Edited by Toshiyuki Miyata)
1. Griffin JH, Zlokovic BV, Mosnier LO. Protein C anticoagulant and cytoprotective pathways. Int. J. Hematol. 95:333-345, 2012
2. Morrissey JH. Polyphosphate: a link between platelets, coagulation and inflammation. Int. J. Hematol. 95:346-352, 2012
3. Denis CV, Lenting PJ. von Willebrand factor: at the crossroads of bleeding and thrombosis. Int. J. Hematol. 95:353-361, 2012
4. Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection
control. Int. J. Hematol. 95:362-370, 2012
Hypoxia and Biology (Edited by Nobuhito Goda)
1. Goda N, Kanai M. Hypoxia-inducible factors and their roles in energy metabolism. Int. J. Hematol. 95:457-463, 2012
2. Mucaj V, Shay JE, Simon MC. Effects of hypoxia and HIFs on cancer metabolism. Int. J. Hematol. 95:464-470, 2012
3. Evans CE, Branco-Price C, Johnson RS. HIF-mediated endothelial response during cancer progression. Int. J. Hematol. 95:471-477,
2012
4. Takubo K, Suda T. Roles of the hypoxia response system in hematopoietic and leukemic stem cells. Int. J. Hematol. 95:478-483, 2012
Disease modeling and treatment by iPS cells (Edited by Koji Eto)
1. Ye Z, Chou BK, Cheng L. Promise and challenges of human iPSC-based hematologic disease modeling and treatment. Int. J.
Hematol. 95:601-609, 2012
2. Ebihara Y, Ma F, Tsuji K. Generation of red blood cells from human embryonic/induced pluripotent stem cells for blood transfusion.
Int. J. Hematol. 95:610-616, 2012
3. Togarrati PP, Suknuntha K. Generation of mature hematopoietic cells from human pluripotent stem cells. Int. J. Hematol.
95:617-623, 2012
4. Watarai H, Yamada D, Fujii S, Taniguchi M, Koseki H. Induced pluripotency as a potential path towards iNKT cell-mediated cancer
immunotherapy.. Int. J. Hematol. 95:624-631, 2012
How to improve the outcome of adult acute myeloid leukemia? (Edited by Tomoki Naoe)
1. Kühnl A, Grimwade D. Molecular markers in acute myeloid leukaemia. Int. J. Hematol. 96:153-163, 2012
2. Stein EM, Tallman MS. Remission induction in acute myeloid leukemia. Int. J. Hematol. 96:164-170, 2012
3. Miyawaki S. Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. Int. J. Hematol. 96:171-177,
2012
4. Ungewickell A, Medeiros BC. Novel agents in acute myeloid leukemia. Int. J. Hematol. 96:178-185, 2012
5. Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int. J. Hematol.
96:186-193, 2012
Epigenetics of Hematopoiesis and Hematopoietic Malignancies (Edited by Atsushi Iwama)
1. Sashida G, Iwama A. Epigenetic regulation of hematopoiesis. Int. J. Hematol. 96:405-412, 2012
2. Chung YR, Schatoff E, Abdel-Wahab O. Epigenetic alterations in hematopoietic malignancies. Int. J. Hematol. 96:413-427, 2012
3. Zhang Y, Chen A, Yan XM, Huang G. Disordered epigenetic regulation in MLL-related leukemia. Int. J. Hematol. 96:428-437, 2012
4. Ogawa S. Splicing factor mutations in myelodysplasia. Int. J. Hematol. 96:438-442, 2012
Current and Future Management of Major Subtypes of Malignant Lymphoma Based on Clinical Trials (Edited by Kensei Tobinai)
1. Eichenauer DA, Engert A. Advances in the treatment of Hodgkin lymphoma. Int. J. Hematol. 96:535-543, 2012
2. Salles G, Ghesquières H. Current and future management of follicular lymphoma. Int. J. Hematol. 96:544-551, 2012
3. Roschewski M, Dunleavy K, Wilson WH. Diffuse large B cell lymphoma: molecular targeted therapy. Int. J. Hematol. 96:552-561,
2012
4. Yamaguchi M. Current and future management of NK/T-cell lymphoma based on clinical trials. Int. J. Hematol.96:562-571, 2012
***2011***
Seven wonders of erythropoiesis (Edited by Kenichi Sawada)
1. Nakamura Y, Hiroyama T, Miharada K, Kurita R. Red blood cell production from immortalized progenitor cell line. Int. J. Hematol.
93: 5-9, 2011.
2. Walkley CR. Erythropoiesis, anemia and the bone marrow microenvironment. Int. J. Hematol. 93: 10-13, 2011
Kaplan J, Ward DM, De Domenico I. The molecular basis of iron overload disorders and iron-linked anemia Int. J. Hematol. 93:14-20,
2011
3. Camaschella C, Pagani A. Iron and erythropoiesis: a dual relationship. Int. J. Hematol. 93:21-26, 2011.
4.
An X, Mohandas N. Erythroblastic islands, terminal erythroid differentiation and reticulocyte maturation. Int. J. Hematol.
93:139-143, 2011.
5. Narla A, Hurst SN, Ebert BL. Ribosome defects in disorders of erythropoiesis. Int. J. Hematol. 93:144-149, 2011.
6. Suzuki M, Shimizu R, Yamamoto M.
Transcriptional regulation by GATA1 and GATA2 during erythropoiesis. Int. J. Hematol.
93:150-155, 2011.
Cancer immunology (Edited by Masaki Yasukawa)
1. Linley AJ, Ahmad M, Rees RC.
Tumour-associated antigens: considerations for their use in tumour immunotherapy. Int. J.
Hematol. 93:263-273, 2011
2. Rezvani K. Peptide vaccine therapy for leukemia. Int. J. Hematol. 93:274-280, 2011
3. Merlo A, Turrini R, Dolcetti R, Zanovello P, Rosato A.
Immunotherapy for EBV-associated malignancies. Int. J. Hematol.
93:281-293, 2011
4. Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y. The
mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol. 93:294-300, 2011
Fanconi anemia and mechanisms of the DNA damage response (Edited by Minoru Takata)
1. Kitao H, Takata M. Fanconi anemia: a disorder defective in the DNA damage response. Int. J. Hematol. 93:417-424, 2011
2. Nakada S. Abnormalities in DNA double-strand break response beyond primary immunodeficiency. Int. J. Hematol. 93: 425-433,
2011
3. Naka K, Hirao A. Maintenance of genomic integrity in hematopoietic stem cells. Int. J. Hematol. 93:434-439, 2011
4. Ying S, Hickson ID. Fanconi anaemia proteins are associated with sister chromatid bridging in mitosis. Int. J. Hematol. 93:440-445,
2011
Role of monoclonal antibodies for the prevention and treatment of graft-versus-host disease (Edited by Yoshinobu Kanda)
1. Levine JE. Implications of TNF-α in the pathogenesis and management of GVHD. Int. J. Hematol. 93:571-577, 2011
2. Kharfan-Dabaja MA, Cutler CS. Rituximab for prevention and treatment of graft-versus-host disease. Int. J. Hematol. 93:578-585,
2011
3. Kanda J, Lopez RD, Rizzieri DA. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int. J. Hematol.
93:586-593, 2011
4.
Davies JK. Costimulatory blockade with monoclonal antibodies to induce alloanergy in donor lymphocytes. Int. J. Hematol.
93:594-601, 2011
Hematopoietic Stem Cell Aging (Edited by Tao Cheng)
1. Chen J. Hematopoietic stem cell development, aging and functional failure. Int. J. Hematol. 94:3-10, 2011
2. Klauke K, de Haan G. Polycomb group proteins in hematopoietic stem cell aging and malignancies. Int. J. Hematol. 94:11-23, 2011
3. Shao L, Li H, Pazhanisamy SK, Meng A, Wang Y, Zhou D. Reactive oxygen species and hematopoietic stem cell senescence. Int. J.
Hematol. 94:24-32, 2011
4. Ju Z, Zhang J, Gao Y, Cheng T. Telomere dysfunction and cell cycle checkpoints in hematopoietic stem cell aging. Int. J. Hematol.
94:33-43, 2011
Signaling and Transcription in the Development of Leukemia (Edited by Mineo Kurokawa)
1. Heidel FH, Mar BG, Armstrong SA. Self-renewal related signaling in myeloid leukemia stem cells. Int. J. Hematol. 94:109-117, 2011
2. Liu H, Chiang MY, Pear WS. Critical roles of NOTCH1 in acute T-cell lymphoblastic leukemia. Int. J. Hematol. 94:118-125, 2011
3. Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. Int. J.
Hematol. 94:126-133, 2011
4. Shima Y, Kitabayashi I. Deregulated transcription factors in leukemia. Int. J. Hematol. 94:134-141, 2011
Understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents (Edited by
Masahiro Abe)
1. Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int. J. Hematol.
94:310-320, 2011
2. Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Barlogie B, Shaughnessy JD Jr. The use of molecular-based risk stratification
and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int. J. Hematol.
94:321-333, 2011
3. Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int. J. Hematol.
94:334-343, 2011
4. Hideshima T, Anderson KC. Novel therapies in MM: from the aspect of preclinical studies. Int. J. Hematol. 94:344-354, 2011
Memorial PIM Adult T-cell Leukemia—from Discovery to Recent Progress (Edited by Masao Matsuoka)
1. Watanabe T. Current status of HTLV-1 infection. Int. J. Hematol. 94:430-434, 2011
2. Yasunaga J, Matsuoka M. Molecular mechanisms of HTLV-1 infection and pathogenesis. Int. J. Hematol. 94:435-442, 2011
3. Ishida T, Ueda R. Antibody therapy for Adult T-cell leukemia–lymphoma. Int. J. Hematol. 94:443-452, 2011